Manufacturing Compliance Woes Wilt Glenmark

An FDA audit flagged up compliance deviations at Glenmark’s manufacturing facility in Baddi, piling up pressure on the firm in an already challenging business environment that saw it report subdued Q2 earnings.

Pharmaceutical production
GLENMARK's BADDI UNIT HAS FAILED TO CLEAR AN FDA AUDIT • Source: Shutterstock

Shares in Glenmark Pharmaceuticals Ltd. were under pressure on Indian bourses after its manufacturing site in Baddi, Himachal Pradesh, failed to pass muster in an FDA audit earlier this month.

The GMP setback comes amid a challenging business environment in the US, one of Glenmark’s key markets. Recent pricing pressure...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip